Proliposomal Dry Powder Inhalation: Design and Development for Pulmonary Antihypertensive Drug Delivery

Abstract

The present study aimed to create a dry powder proliposomal inhaler that would administer a medication for hypertension to the lungs. The pulmonary method of administration also has many benefits because the alveolar membrane is very thin and highly permeable, which lets different APIs be absorbed by the lungs. After getting information from the in vitro drug penetration, RSM analysis was used to find out how each measure affected the results. The best mix of cholesterol and soya phosphatidylcholine (SPC) was picked from the different amounts. Five grammes of SPC, six grammes of cholesterol, and a stirring speed of 210 rpm (F5) were picked as the amounts. It shows 94.81% in vitro permeability for 12 h with the improved preparation. Several different kinetic models are used to display the drug release kinetics data from in vitro drug release research. We were able to comprehend the drug's release mechanism thanks to the curve fitting findings of the generated formulae' rate of entrance. We employed non-Fickian diffusion to account for the medication release. Based on the "n" number of 0.6300, this suggested both a diffusion and growth process. Also, Higuchi gave the best answer for how the drug was released, as shown by the plots' highest level of regularity (r2 = 0.9990) and Higuchi's best fit for the drug release. In the improved composition, particles with a size of 683 nm were seen. Based on the above findings, atenolol proliposomes show potential as a way to give medicine to treat high blood pressure.